Objective: To explore the correlation between coagulation indices and lymphocyte-derived indexes and the prognosis of patients with lung adenocarcinoma receiving combined therapy with platinum-based doublet chemotherapy and bevacizumab. Methods: A total of 43 patients with advanced lung adenocarcinoma who received platinum-based doublet chemotherapy combined with bevacizumab were included, and their clinical data were retrospectively analyzed. According to the levels of coagulation index [fibrinogen (Fib)] and lymphocyte-derived indexes [lymphocyte-to-fibrinogen ratio (LFR), platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR)], patients were divided into low-level and high-level groups. Progression-free survival (PFS) was compared between the low- and high-level groups for each index. Univariate analysis and multivariate Cox regression analysis were applied to identify factors influencing the prognosis of patients undergoing this combined treatment regimen. Results: PFS in the low-level Fib group was significantly higher than that in the high-level Fib group (P < 0.05). PFS in the high-level LFR group was significantly higher than that in the low-level LFR group (P < 0.05). PFS in the low-level PLR group was significantly higher than that in the high-level PLR group (P < 0.05). PFS in the low-level NLR group was significantly higher than that in the high-level NLR group (P < 0.05). Univariate analysis of baseline clinical characteristics revealed that PFS differed significantly among patients with different statuses of liver metastasis and maintenance treatment (P < 0.05). Multivariate Cox regression analysis indicated that PLR, NLR, and maintenance treatment were independent prognostic factors for patients with lung adenocarcinoma (P < 0.05). Conclusion: Fibrinogen (Fib), lymphocyte-to-fibrinogen ratio (LFR), platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), liver metastasis, and maintenance treatment are all associated with PFS in patients with lung adenocarcinoma treated with platinum-based doublet chemotherapy combined with bevacizumab. Specifically, low PLR, low NLR, and receipt of maintenance treatment are independent predictors of longer progression-free survival.